Testosterone nadir and clinical outcomes in patients with advanced prostate cancer: Post hoc analysis of triptorelin pamoate Phase III studies.

Published in: BJUI compass (2024)

Low nadir testosterone achieved during treatment with the LHRH agonist triptorelin was associated with improved OS and DSS in patients with advanced prostate cancer.

Keyphrases

prostate cancer
phase iii
radical prostatectomy
open label
replacement therapy
clinical trial
double blind
phase ii
placebo controlled